• FITC Goat Anti-Rabbit IgG (H+L) Antibody: Gut Assays

  2026-08-12

  Translate rabbit-primary immunofluorescence, flow cytometry, and fluorescent tissue staining into a practical workflow for studying DON-induced intestinal injury. This guide connects FITC signal amplification with the reference study’s lycopene–ERK findings while emphasizing controls, quantitative imaging, and troubleshooting.

• Linarin, c-FOS/ARG2, and Insulin Resistance

  2026-08-11

  This 2025 Phytotherapy Research study combines network pharmacology, molecular docking, palmitate-treated HepG2 cells, and high-fat diet-fed mice to identify linarin as a bioactive Lycii Cortex constituent associated with improved insulin resistance. Its findings connect enhanced glucose uptake and reduced inflammation with the c-FOS/ARG2 signaling axis, while also illustrating how 2-NBDG staining can support mechanistic glucose metabolism research.

• In Vitro Drug Response: Growth Inhibition and Cell Death

  2026-08-10

  Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central finding is that most tested drugs influence both proliferation and cell death, but the balance and timing of these effects differ, with important consequences for in vitro study design and interpretation.

• Fasudil (HA-1077) HCl: ROCK Inhibitor Workflows

  2026-08-09

  Build reproducible experiments for Rho/ROCK pathway inhibition, cell migration suppression, and apoptosis analysis with Fasudil (HA-1077) HCl. This guide connects practical ROCK assays with recent Hippo-pathway research while clearly separating validated evidence from exploratory cross-talk studies.

• Alda 1: A Mechanistic Guide to ALDH2 Research

  2026-08-08

  Alda 1 is an ALDH2 activator for dissecting aldehyde detoxification, cardiac stress responses, and genotype-dependent enzyme rescue. This guide connects biochemical assay design with cardioprotection in ischemia, pressure-overload models, and radiation-induced dermatitis mitigation while defining the limits of translational interpretation.

• Lymphodepletion and Neoantigen-Directed T Cell Therapy

  2026-08-07

  Sagie et al. identified a KRAS.G12V-specific T cell receptor and showed that lymphodepleting chemotherapy can improve neoantigen presentation through immunoproteasome activation and increased HLA-I surface expression. The study provides a mechanistic framework for combining chemotherapy with TCR-T cells, tumor-infiltrating lymphocytes, or T cell engagers while highlighting the need to optimize combination regimens rather than treating lymphodepletion as background conditioning.

• Dimetridazole: Mechanistic Synergy & Strategy Against MDR Ba

  2026-08-07

  Explore how Dimetridazole, a 1,2-dimethyl-5-nitroimidazole, enables translational researchers to target multidrug-resistant bacteria through membrane disruption and quorum sensing inhibition. This article blends mechanistic insight, protocol guidance, and a strategic perspective on leveraging Dimetridazole in advanced infection models and combination assays, extending far beyond basic product summaries.

• Galectin-1 Impairs Autophagy to Drive Hepatic Steatosis via

  2026-08-06

  This study uncovers a direct mechanistic link between galectin-1 and impaired hepatic autophagy in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). By demonstrating how galectin-1 interacts with FIP200 to disrupt autophagy and promote steatosis and insulin resistance, the findings highlight a novel regulatory axis and potential therapeutic target for metabolic liver disorders.

• EV-Transferred ACLY Drives Monocyte-to-TAM Differentiation i

  2026-08-06

  This study reveals that hepatocellular carcinoma (HCC) cells promote tumor-associated macrophage (TAM) differentiation by transferring ATP-citrate lyase (ACLY) to monocytes via extracellular vesicles. The findings highlight a metabolic mechanism fueling HCC progression and present new avenues for immunometabolic intervention.

• EZ Cap™ Firefly Luciferase mRNA: Molecular Engineering for P

  2026-08-05

  Explore how EZ Cap™ Firefly Luciferase mRNA empowers molecular biology with enhanced stability, translation, and quantitative assay precision. This article reveals the unique impact of Cap1 engineering and LNP delivery optimization for next-generation reporter applications.

• AZD8055: Technical Guidance for mTOR Pathway Inhibition

  2026-08-05

  AZD8055 is a selective, ATP-competitive mTOR inhibitor for preclinical research dissecting mTORC1 and mTORC2 signaling in cancer and metabolic models. It is not suitable for studies prioritizing clinical efficacy endpoints or requiring water solubility. Use AZD8055 for mechanistic analysis of mTOR-regulated pathways under controlled, well-validated laboratory conditions.

• Homoharringtonine Rapidly Clears SARS-CoV-2 Infections In Vi

  2026-08-04

  A recent study demonstrates that homoharringtonine, a cytotoxic alkaloid, can clear SARS-CoV-2 from the upper respiratory tract within 2–4 days using targeted delivery strategies. This work highlights the potential of protein synthesis inhibitors as first-line defenses in future coronavirus epidemics and provides a translational bridge between cancer biology and antiviral research.

• Neuroligin 1 Loss Drives Repetitive Behaviors via Striatal D

  2026-08-04

  This study identifies Neuroligin 1 deficiency in striatal D2 receptor-expressing medium spiny neurons as a key driver of autistic-like repetitive behaviors, mediated through altered PKC signaling and neuronal hyperactivity. The findings clarify cell-type specific mechanisms for restricted and repetitive behaviors in autism spectrum disorder and suggest new intervention points for translational research.

• Recombinant Human IL-15: Optimizing T and NK Cell Assays

  2026-08-03

  Leverage the high bioactivity and purity of Recombinant Human IL-15 (E.coli, Tag Free, Lyophilized) from APExBIO to accelerate T cell activation and NK cell proliferation workflows. This guide translates recent neuroimmune research into actionable protocols and troubleshooting insights for immune response modulation in advanced experimental models.

• SGI-1027: Transforming Epigenetic Modulation in Cancer Resea

  2026-08-03

  This thought-leadership article explores the mechanistic nuance and translational impact of SGI-1027, a potent DNA methyltransferase inhibitor. Integrating advanced experimental insights, competitive benchmarking, and strategic guidance, it clarifies SGI-1027's role in reactivating tumor suppressor genes and shaping the next wave of cancer epigenetics research. The discussion goes beyond standard product descriptions, offering evidence-driven protocols and a forward-looking vision for translational applications.

446 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page